Bethesda III类(AUS/FLUS)亚分类:基于中国国家癌症中心ThinPrep涂片的甲状腺FNA细胞学研究
该研究回顾中国国家癌症中心2013年7月至2018年12月的甲状腺细针穿刺(FNA)病例,12,913例中1,053例(8.2%)为AUS/FLUS,对222例有手术随访的AUS/FLUS涂片按2017 TBSRTC建议亚分类。结果185/222(83.3%)为恶性,AUS-C1组最常见(62.1%)且恶性风险最高(92.6%),认为亚分类有助于识别高恶性风险结节并改善管理。
要点
- AUS/FLUS占甲状腺FNA的8.2%,恶性风险在不同医疗中心差异大。
- 亚分类中AUS-C1最常见(62.1%)且恶性风险最高(92.6%)。
- AUS/FLUS亚分类可能有助于识别高恶性风险结节并改善管理。
核心结论
- AUS/FLUS为异质性类别,其恶性风险在不同医疗中心差异很大。
- AUS/FLUS亚分类可能有助于识别该类别中高恶性风险的结节并改善管理。
研究设计与样本
- 回顾性研究,纳入2013年7月至2018年12月中国国家癌症中心12,913例甲状腺FNA,其中1,053例(8.2%)为AUS/FLUS。
- 对222例有手术随访的AUS/FLUS患者涂片按2017 TBSRTC建议进行亚分类。
- 195例持续诊断为AUS/FLUS的穿刺样本被亚分类为AUS-C1、AUS-C2、AUS-A、AUS-C&A、AUS-H、AUS-NOS和AUS-L。
主要发现
- 222例AUS/FLUS结节中185例(83.3%)为恶性。
- 亚分类占比:AUS-C1最常见(62.1%),其次AUS-C&A(12.8%)、AUS-C2(10.8%)、AUS-H(6.7%)、AUS-NOS(5.6%)、AUS-L(1.5%)、AUS-A(0.5%)。
- AUS-C1组恶性风险最高(92.6%),与AUS-C&A(P=.171)、AUS-C2(P=.001)、AUS-H(P=.001)、AUS-NOS(P<.001)组存在差异。
关键数值与推荐
- AUS/FLUS亚分类依据2017 TBSRTC建议,分为AUS-C1、AUS-C2、AUS-A、AUS-C&A、AUS-H、AUS-NOS和AUS-L。
- AUS-C1组恶性风险92.6%,AUS-C&A组P=.171,AUS-C2组P=.001,AUS-H组P=.001,AUS-NOS组P<.001。
临床怎么用
- 对AUS/FLUS结节可按2017 TBSRTC建议进行亚分类,以辅助识别高恶性风险结节。
- 亚分类结果可能有助于改善AUS/FLUS结节的管理决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The atypia of an undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) is a heterogeneous category, which includes various cell patterns. The subclassification of AUS/FLUS was suggested in the 2017 TBSRTC. However, the risk of malignancy (ROM) associated with different subgroups remains unresolved. Herein, AUS/FLUS aspirates were subclassified, from which the ROM of each subgroup was determined. METHODS: All cases undergoing fine-needle aspiration (FNA) from July 2013 to December 2018 were reviewed. Of 12,913 thyroid FNAs, 1053 (8.2%) were AUS/FLUS. The slides of 222 patients with AUS/FLUS with surgical follow-up were reviewed and subclassified according to the recommendations of the 2017 TBSRTC. There were 195 aspirates consistently diagnosed as AUS/FLUS and subclassified as cytologic atypia 1 (AUS-C1); cytologic atypia 2 (AUS-C2); architectural atypia (AUS-A); cytologic and architectural atypia (AUS-C&A); Hürthle cell aspirates (AUS-H); atypia, not otherwise specified (AUS-NOS); and atypical lymphoid cells, rule out lymphoma (AUS-L). RESULTS: Malignancy was identified in 83.3% (185 of 222) of the AUS/FLUS nodules. The AUS-C1 group was the most common (62.1%), followed by the AUS-C&A (12.8%), AUS-C2 (10.8%), AUS-H (6.7%), AUS-NOS (5.6%), AUS-L (1.5%), and AUS-A (0.5%) groups. AUS-C1 had the highest ROM (92.6%) among the groups and varied significantly from that of the AUS-C&A (P = .171), AUS-C2 (P = .001), AUS-H (P = .001), and AUS-NOS (P < .001) groups. CONCLUSIONS: As a heterogeneous category of TBSRTC, the ROM for AUS/FLUS varies greatly among medical centers. Subclassification of AUS/FLUS might be helpful in identifying nodules with a high ROM in this category and improving the management of such nodules.
引用
- Zhao H, Guo H, Zhao L, et al. Subclassification of the Bethesda Category III (AUS/FLUS): A study of thyroid FNA cytology based on ThinPrep slides from the National Cancer Center in China. Cancer Cytopathol. 2021. PMID: 34139103. doi:10.1002/cncy.22417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。